@Mateo335 I agree the oral vs IV is a massive advantage for 434. Not just the well known benefits like you mention, but its important to remember this is a movement disorder that is getting treated, patients experiencing tremors and involuntary movements which could make the IV admin more complicated for nurse and unpleasant for patient, compared to say a cancer patient getting an infusion. Patients and physicians would have this in mind if having a choice between therapies IMO.
Lundbeck are already recruiting for their ph 3 study, A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA) (MASCOT) (NCT06706622). 18month blinded, 18 month unblinded. You'd think the whole MSA world would of had eyes on the 201 readout so it will be interesting how 434, which now appears to be a superior option, has on their recruitment. Interesting their inclusion criteria is allowing up to 5 years of motor MSA symptoms, I would of thought they would of reduced this down to around 3.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)